Condition
Acute Agitation
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 3 (1)
P 4 (1)
Trial Status
Unknown2
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05803642Phase 3UnknownPrimary
A Study of Olanzapine in Patients With Acute Agitation
NCT03246620Phase 4TerminatedPrimary
Oral Olanzapine Versus Haloperidol or Diazepam
NCT03624322Phase 1CompletedPrimary
Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101
NCT02512705Not ApplicableUnknownPrimary
Medical Monitoring for Agitated Patients Pilot RCT - Medical Monitoring
Showing all 4 trials